SLC5A2 and hydrops fetalis: Treatment with SGLT-2 inhibitors improves the utilization of ketone bodies in HF through multiple pathways, such as increased hepatic production of ketone bodies, regulating mitochondrial metabolism, activating nutrient deprivation signaling pathway, and promoting the utilization of cardiac ketone bodies [64,74,75,76,77,78].